- Home
- LYEL vs SCPH Comparison
LYEL vs SCPH Comparison
Compare LYEL & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYEL
- SCPH
- Stock Information
- Founded
- LYEL 2018
- SCPH 2013
- Country
- LYEL United States
- SCPH United States
- Employees
- LYEL N/A
- SCPH N/A
- Industry
- LYEL Biotechnology: Pharmaceutical Preparations
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- LYEL Health Care
- SCPH Health Care
- Exchange
- LYEL Nasdaq
- SCPH Nasdaq
- Market Cap
- LYEL 207.7M
- SCPH 173.6M
- IPO Year
- LYEL 2021
- SCPH 2017
- Fundamental
- Price
- LYEL $0.54
- SCPH $2.63
- Analyst Decision
- LYEL Sell
- SCPH Strong Buy
- Analyst Count
- LYEL 2
- SCPH 3
- Target Price
- LYEL $1.00
- SCPH $14.00
- AVG Volume (30 Days)
- LYEL 866.3K
- SCPH 624.1K
- Earning Date
- LYEL 03-11-2025
- SCPH 03-19-2025
- Dividend Yield
- LYEL N/A
- SCPH N/A
- EPS Growth
- LYEL N/A
- SCPH N/A
- EPS
- LYEL N/A
- SCPH N/A
- Revenue
- LYEL $61,000.00
- SCPH $36,332,000.00
- Revenue This Year
- LYEL N/A
- SCPH $134.20
- Revenue Next Year
- LYEL N/A
- SCPH $99.40
- P/E Ratio
- LYEL N/A
- SCPH N/A
- Revenue Growth
- LYEL N/A
- SCPH 167.28
- 52 Week Low
- LYEL $0.48
- SCPH $2.50
- 52 Week High
- LYEL $3.15
- SCPH $5.65
- Technical
- Relative Strength Index (RSI)
- LYEL 43.44
- SCPH 30.22
- Support Level
- LYEL $0.53
- SCPH $2.87
- Resistance Level
- LYEL $0.63
- SCPH $3.08
- Average True Range (ATR)
- LYEL 0.07
- SCPH 0.19
- MACD
- LYEL -0.00
- SCPH -0.02
- Stochastic Oscillator
- LYEL 26.39
- SCPH 18.84
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.